Remove 2021 Remove Safety Remove Treatments
article thumbnail

And Then There Were Six…FDA Green Lights Hugel’s Toxin for Glabellar Lines

The Dermatology Digest

Food and Drug Administration (FDA) has given its nod to Letybo (foletibotulinumtoxinA) for the treatment of moderate-to-severe glabellar lines in adults. Hugel filed its first Biologics License Application in 2021, which was rejected by the FDA in 2022. Now, there are six neuromodulators approved for cosmetic use in the U.S.:

article thumbnail

Biosimilar News: FDA Approves High-concentration, Citrate-free Formulation of Cyltezo, a Biosimilar to Humira

The Dermatology Digest

“With this FDA approval, we are now able to offer both high- and low-concentration, citrate-free formulations of Cyltezo, further expanding treatment access for patients living with certain chronic inflammatory diseases,” says Stephen Pagnotta, Executive Director and Biosimilar Commercial Lead at Boehringer Ingelheim, in a news release.

Clinic 36
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA to Review Biofrontera’s sNDA for Ameluz Dosage Increase

The Dermatology Digest

Food and Drug Administration (FDA) has issued a “no filing review issues identified” letter regarding Biofrontera’s sNDA (supplementary New Drug Application) which aims to increase the maximally approved dosage from one to three tubes of Ameluz per treatment.

Safety 28
article thumbnail

Sulforaphane Could Help Dissolve Blood Clots and Prevent Stroke

Aesthetics Advisor

Sulforaphane, a natural chemical found in broccoli and other cruciferous vegetables, could potentially revolutionize the treatment of stroke. Current Stroke Treatment Every 40 seconds, someone in the United States suffers a stroke. In 2021, strokes accounted for one in every six deaths from cardiovascular disease.

Diet 66
article thumbnail

Biosimilar Watch: FDA Accepts BLA for Proposed Stelara Biosimilar 

The Dermatology Digest

Ustekinumab is approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. The clinical results demonstrated that DMB-3115 and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of quality, safety and efficacy.

article thumbnail

Fenbendazole Joe Tippens Protocol: A Simple Step-by-Step Guide (2023)

Aesthetics Advisor

Disclaimer: We in no way endorse the Joe Tippens Cancer Protocol as a cure for cancer, and as always, you should consult your physician before starting any new medications or treatment plans. However, it is also being used by humans in a cancer treatment method known as the Joe Tippens Protocol. What Is Fenbendazole? chemotherapy?

Therapy 69
article thumbnail

New for 2022, California Estheticians Can Perform Brow Lamination, Lash Lifts & Tints!

California Skincare Supply

Follow the link above to learn more. Oct 2021 Important Announcement for California Estheticians Who can do lash lifting, lash tinting, and brow lamination in California in 2022? “ You can access FDA Eye Cosmetic Safety information at: [link]. Estheticians can! That's who! So, it can’t be clearer.